Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.

"data availability all data are available from the gdc legacy archive ( https://portal gdc cancer gov/legacy-archive ). supplementary material associated with this article can be found in the online version at doi"

"Declaration of Competing Interest All authors declare no conflict of interest related to this study. Mills reports SAB/Consultant: AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. Stock/Options/Financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, Turbine. Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring, outside the submitted work."

"AcknowledgmentsThis work was supported by grants from National Cancer Institute U01CA217842 (G.B.M.) and CPRIT grant RR170048 (C.I.A.)."